HOME >> BIOLOGY >> NEWS
Marimastat produces comparable survival rates to chemotherapy in some advanced pancreatic cancer patients

Marimastat, a matrix metalloproteinase inhibitor, offers a similar survival benefit to chemotherapy in patients with non-metastatic pancreatic cancer, but with fewer side effects, reports an international team of researchers from the United States and Britain.

The randomized clinical trial compared the effects of three different doses of marimastat with the chemotherapy drug gemcitabine in 414 patients with advanced pancreatic cancer. During this clinical trial, gemcitabine was approved for use in pancreatic cancer, and is now considered the standard of care.

According to the study, the one-year survival rate for patients with localized cancer was 20 percent for patients given the highest dose of marimastat and 19 percent for patients treated with gemcitabine. Although patients taking gemcitabine reported greater improvements in pain and mood, fewer toxic side effects (e.g., pulmonary complications and nausea) were reported in patients taking marimastat versus gemcitabine (12 percent versus 22 percent, respectively).

Marimastat did not show benefit in lower doses or in patients with metastatic pancreatic cancer. The one-year survival rate for patients taking lower doses of marimastat was 14 percent.

Researchers say marimastat appears to benefit some non-metastatic patients and suggest the agent be tested in those patients in combination with gemcitabine. "Five years ago, patients with advanced pancreatic cancer did not have any good treatment options, but gemcitabine and newly engineered drugs like marimastat are giving us hope," says the study leader Simon Bramhall, from the Queen Elizabeth Hospital, Birmingham, England. "These clinical trial results are encouraging and suggest that targeted molecular therapy may benefit some patients."

Matrix metalloproteinase inhibitors restrict the growth and spread of solid tumors by blocking blood vessel growth to the site of tumors. Marimastat is also being tested in ovarian a
'"/>

Contact: Carrie Bittman
bittmanc@asco.org
703-299-1016
American Society of Clinical Oncology
30-Jul-2001


Page: 1 2

Related biology news :

1. Genetic modification of linseed produces healthier omega 3 and 6 fatty acids
2. Spontaneous mutation produces new MAO A/B knockout mouse
3. Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies
4. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients
5. First genetic comparison of purebred domestic dogs produces surprises
6. Biological computer diagnoses cancer and produces drug in a test tube
7. High-fat fast-food breakfast produces rush of inflammatory factors into blood stream, UB study finds
8. Oil exploitation in Ecuadors Amazon basin produces a public health emergency
9. Method produces uniform, self-assembled nanocells
10. Scientists develop plant that produces potential anti-carcinogen
11. Brains master molecule produces same behavior in mice from three different psychostimulant drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/1/2017)... BEDFORD, Mass. , March 1, 2017  Aware, ... and services, announced that Richard P. Moberg ... Officer and co-President and Chief Financial Officer and Treasurer ... will continue to serve as a member of the ... T. Russell , Aware,s co-Chief Executive Officer and co-President, ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
(Date:2/21/2017)... and PORTLAND, Ore. , ... and the Avamere Family of Companies (Avamere Health Services, ... announced a six-month research study that will apply the ... eldercare at senior living and health centers. By analyzing ... hopes to gain insights into physical and environmental conditions, ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , ... March 23, 2017 , ... ... recently selected by the Connecticut Technology Council (CTC) as a 2017 Women of ... thirteenth annual Women of Innovation Awards Dinner. , The dinner recognizes women accomplished ...
(Date:3/23/2017)...  Agriculture technology company Cool Planet has closed on ... to commercialize its Cool Terra and Cool Fauna Engineered ... that are simultaneously profitable as well as sustainable and ... months. This latest round of funding was led by ... The company,s primary product, Cool Terra, can improve ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... regeneration from small lab samples to full-size tissues, bones, even whole organs to ... vascular system that delivers blood deep into the developing tissue. , Current ...
(Date:3/22/2017)... , March 22, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage ... drug delivery systems, announced today that Dr. ... deliver a presentation titled, "Oral Insulin for Diabetes ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference ...
Breaking Biology Technology:
Cached News: